In the News

Diabetes patients lost more weight with time-restricted eating than calorie counting

Over the course of six months, eating only between noon and 8 p.m. had a greater impact on weight loss and a similar effect on HbA1c levels compared with reducing energy intake by 25%, according to a small randomized trial of patients with type 2 diabetes and obesity.

Women more likely to have pain with diabetic peripheral neuropathy

Cardiometabolic factors traditionally associated with microvascular disease were not associated with risk for painful diabetic peripheral neuropathy in patients with type 1 diabetes, a European study found.

High-normal albumin-to-creatinine ratio associated with CV events in type 2 diabetes

Patients with an elevated urinary albumin-to-creatinine ratio, even below 30 mg/g, were at increased risk for major adverse cardiovascular (CV) events, a post hoc analysis of the ACCORD trial found.

MKSAP quiz: Treating diabetes and cardiovascular disease

This month's quiz asks readers to choose a medication for a 68-year-old man with a history of type 2 diabetes, hyperlipidemia, hypertension, and aortofemoral bypass surgery 2 years ago.

Spotlight on novel therapies for type 1 diabetes

Manufacturer trials reported the effects of weekly insulin and teplizumab in patients with type 1 diabetes, while recent reviews looked at preventing beta-cell loss with various therapeutics and using drugs approved for type 2 diabetes to combat chronic kidney disease in type 1.

In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes

The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on gout in patients with type 2 diabetes or heart failure (HF) may allow reduced polypharmacy when treatment for gout is also needed, an ACP Journal Club commentary said.

In adults with BMI ≥27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk

The new drugs known as “twincretins” represent a major breakthrough for patients with overweight or obesity, prediabetes, or diabetes, but obstacles will include supply, lack of cost-effectiveness evidence, and insurance coverage, an ACP Journal club commentary said.

Rosuvastatin, atorvastatin compared on effectiveness, safety in industry-funded trial

Analysis of a randomized trial in South Korea found that patients randomized to rosuvastatin developed type 2 diabetes requiring medication at a rate of 7.2%, compared to 5.3% among those given atorvastatin.

Two diabetes drugs go generic

A dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter-2 inhibitor recently had first-time generic versions approved.